2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.116 (Poster) Utilization of Extended-interval, Fixed-dosing of Durvalumab, Every 4 weeks, in U.S. Patients with Unresectable Stage III NSCLC Following Concurrent Chemoradiation

PP01.116 (Poster) Utilization of Extended-interval, Fixed-dosing of Durvalumab, Every 4 weeks, in U.S. Patients with Unresectable Stage III NSCLC Following Concurrent Chemoradiation

Back to course

Pdf Summary

This retrospective cohort study aimed to describe the utilization and discontinuation of durvalumab, a medication used to treat stage III unresectable non-small cell lung cancer (uNSCLC), in U.S. patients following concurrent chemoradiation. The study was conducted in a large integrated healthcare delivery system, Kaiser Permanente Southern & Northern California, which adopted a fixed-dosing schedule of durvalumab every four weeks (Q4W) during the COVID-19 pandemic.<br /><br />The study included adult patients with stage III uNSCLC who had at least 12 months of healthcare coverage prior to starting durvalumab and initiated the treatment between March 1, 2019, and December 31, 2021. The patients were divided into two groups: those who switched from a dosing schedule of every two weeks (Q2W) to Q4W (switchers) and those who initiated Q4W dosing.<br /><br />The results showed that out of the 102 eligible patients, 42 were switched from Q2W to Q4W dosing, and 60 initiated Q4W dosing. The study found that the Q4W dosing schedule was well tolerated in the real-world cohort, with nearly half of the patients completing one year of treatment. The most common reasons for discontinuation were disease progression and pneumonitis.<br /><br />The median time to durvalumab initiation was 38.0 days, and the median duration of treatment (DoT) was 10.0 months overall, including treatment interruptions. The DoT and discontinuation rates were comparable to the findings of previous studies with Q2W dosing, despite the older age and increased comorbidities in this study population.<br /><br />The study provides valuable real-world evidence on the utilization and discontinuation of durvalumab in patients with stage III uNSCLC following concurrent chemoradiation. The results support the use of a Q4W dosing schedule as a well-tolerated and effective treatment option for these patients. Further research is needed to explore the factors influencing treatment duration and identify strategies to improve treatment completion rates.

Asset Subtitle

Reina Haque

Keywords

retrospective cohort study

utilization

discontinuation

durvalumab

stage III unresectable non-small cell lung cancer

uNSCLC

concurrent chemoradiation

U.S. patients

fixed-dosing schedule

COVID-19 pandemic